Health Benefits, Risks, and Cost-effectiveness of Influenza Vaccination of Children

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2006 Dec 21

PMID 17176570

Citations 41

Authors

Lisa A Prosser

Carolyn Buxton Bridges

Timothy M Uyeki

Virginia L Hinrichsen

Martin I Meltzer

Noelle-Angelique M Molinari

Benjamin Schwartz

William W Thompson

Keiji Fukuda

Tracy A Lieu

Affiliations

Soon will be listed here.

Abstract

We estimated cost-effectiveness of annually vaccinating children not at high risk with inactivated influenza vaccine (IIV) to range from US $12,000 per quality-adjusted life year (QALY) saved for children ages 6-23 months to $119,000 per QALY saved for children ages 12-17 years. For children at high risk (preexisting medical conditions) ages 6-35 months, vaccination with IIV was cost saving. For children at high risk ages 3-17 years, vaccination cost $1,000-$10,000 per QALY. Among children notat high risk ages 5-17 years, live, attenuated influenza vaccine had a similar cost-effectiveness as IIV. Risk status was more important than age in determining the economic effects of annual vaccination, and vaccination was less cost-effective as the child's age increased. Thus, routine vaccination of all children is likely less cost-effective than vaccination of all children ages 6-23 months plus all other children at high risk.

Citing Articles

Respiratory Syncytial Virus Sequelae Among Adults in High-Income Countries: A Systematic Literature Review and Meta-analysis.

Ubamadu E, Betancur E, Gessner B, Menon S, Vroling H, Curcio D Infect Dis Ther. 2024; 13(7):1399-1417.

PMID: 38789901 PMC: 11219677. DOI: 10.1007/s40121-024-00974-7.

Cost-Effectiveness of Intranasal Live-Attenuated Influenza Vaccine for Children: A Systematic Review.

Chan K, Wong C, Choi H Vaccines (Basel). 2022; 10(9).

PMID: 36146544 PMC: 9505322. DOI: 10.3390/vaccines10091466.

Protocol for the economic evaluation of COVID-19 pandemic response policies.

Chua B, Huynh V, Lou J, Goh F, Clapham H, Teerawattananon Y BMJ Open. 2021; 11(9):e051503.

PMID: 34521677 PMC: 8441219. DOI: 10.1136/bmjopen-2021-051503.

Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review.

Fens T, de Boer P, van Puijenbroek E, Postma M Vaccines (Basel). 2021; 9(2).

PMID: 33540633 PMC: 7913116. DOI: 10.3390/vaccines9020111.

Evaluating Partial Series Childhood Vaccination Services in a Mobile Clinic Setting.

Chen W, Misra S, Zhou F, Sahni L, Boom J, Messonnier M Clin Pediatr (Phila). 2020; 59(7):706-715.

PMID: 32111120 PMC: 8721745. DOI: 10.1177/0009922820908586.

References

Ekwueme D, Strebel P, Hadler S, Meltzer M, Allen J, Livengood J . Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med. 2000; 154(8):797-803. DOI: 10.1001/archpedi.154.8.797. View

Margolis H, Coleman P, Brown R, Mast E, Sheingold S, Arevalo J . Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA. 1995; 274(15):1201-8. View

. Recommendations for influenza immunization of children. Pediatrics. 2004; 113(5):1441-7. DOI: 10.1542/peds.113.5.1441. View

White C, Koplan J, Orenstein W . Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health. 1985; 75(7):739-44. PMC: 1646302. DOI: 10.2105/ajph.75.7.739. View

Cohen G, Nettleman M . Economic impact of influenza vaccination in preschool children. Pediatrics. 2000; 106(5):973-6. DOI: 10.1542/peds.106.5.973. View

Pisu M, Meltzer M, Hurwitz E, Haber M . Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study. Pharmacoeconomics. 2005; 23(1):55-67. DOI: 10.2165/00019053-200523010-00005. View

Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P . Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child. 1991; 145(4):445-8. DOI: 10.1001/archpedi.1991.02160040103017. View

Hall C, COONEY M, Fox J . The Seattle virus watch. IV. Comparative epidemiologic observations of infections with influenza A and B viruses, 1965-1969, in families with young children. Am J Epidemiol. 1973; 98(5):365-80. DOI: 10.1093/oxfordjournals.aje.a121566. View

Hoberman A, Greenberg D, Paradise J, Rockette H, Lave J, Kearney D . Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003; 290(12):1608-16. DOI: 10.1001/jama.290.12.1608. View

10.

Halloran M, Longini I, Cowart D, Nizam A . Community interventions and the epidemic prevention potential. Vaccine. 2002; 20(27-28):3254-62. DOI: 10.1016/s0264-410x(02)00316-x. View

11.

Luce B, Zangwill K, Palmer C, Mendelman P, Yan L, Wolff M . Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics. 2001; 108(2):E24. DOI: 10.1542/peds.108.2.e24. View

12.

Monto A, Sullivan K . Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect. 1993; 110(1):145-60. PMC: 2271959. DOI: 10.1017/s0950268800050779. View

13.

Fox J, COONEY M, Hall C, Foy H . Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol. 1982; 116(2):228-42. DOI: 10.1093/oxfordjournals.aje.a113408. View

14.

Lee G, LeBaron C, Murphy T, Lett S, Schauer S, Lieu T . Pertussis in adolescents and adults: should we vaccinate?. Pediatrics. 2005; 115(6):1675-84. DOI: 10.1542/peds.2004-2509. View

15.

Neuzil K, Zhu Y, Griffin M, Edwards K, Thompson J, Tollefson S . Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002; 185(2):147-52. DOI: 10.1086/338363. View

16.

White T, Lavoie S, Nettleman M . Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics. 1999; 103(6):e73. DOI: 10.1542/peds.103.6.e73. View

17.

Lieu T, McGuire T, Hinman A . Overcoming economic barriers to the optimal use of vaccines. Health Aff (Millwood). 2005; 24(3):666-79. DOI: 10.1377/hlthaff.24.3.666. View

18.

Prosser L, Ray G, OBrien M, Kleinman K, Santoli J, Lieu T . Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics. 2004; 113(2):283-90. DOI: 10.1542/peds.113.2.283. View

19.

Monto A, Koopman J, Longini Jr I . Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981. Am J Epidemiol. 1985; 121(6):811-22. DOI: 10.1093/oxfordjournals.aje.a114052. View

20.

Szilagyi P, Iwane M, Schaffer S, Humiston S, Barth R, McInerny T . Potential burden of universal influenza vaccination of young children on visits to primary care practices. Pediatrics. 2003; 112(4):821-8. DOI: 10.1542/peds.112.4.821. View